Clinical Trial Update: A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Tradipitant for nausea and vomiting induced by GLP-1 receptor agonist use in obesity is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nausea
• Obesity
• Vomiting

Drugs mentioned

• Tradipitant (tradipitant)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Nausea and Vomiting, Obesity | Phase 3 | Status: RECRUITING